Trial Profile
A phase 2 study of capecitabine (R340) in patients who have failed previous treatment with taxane for metastatic breast cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Jul 2018
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary)
- Indications Breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Chugai Pharmaceutical
- 17 Jun 2016 New trial record